By: Eric Sagonowsky
As biopharma companies of all stripes devote more time and attention to AI-based drug discovery and development, healthcare PE firm Altaris is bolstering its presence in the field through M&A.
Eric Sagonowsky is a Senior Editor at the Fierce life sciences group. He focuses on themes related to medicine and healthcare, pharmaceuticals, and cybersecurity, covering topics such as cyber attacks, data breaches, and pharmaceutical regulation. Eric's work has been featured in Fierce Biotech and Fierce Pharma.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Eric Sagonowsky's articles predominantly cover announcements from the healthcare and pharmaceutical sectors, with a focus on FDA approvals, drug companies, medical research, and broader healthcare topics. His coverage suggests he would likely be interested in receiving pitches related to new drug approvals, clinical trial results or significant developments within pharmaceutical companies.
Given his extensive press release coverage (28%), Eric is likely open to receiving news directly from pharmaceutical companies about their latest products and milestones. Additionally, given the emphasis on government announcements (16%), he might also be interested in regulatory changes impacting the industry.
Since there is no specified geographic focus for Eric's coverage area, it can be inferred that he covers global developments within the pharmaceutical and healthcare industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .